Clinical Trial Update: An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate [Phase 1]

View source ↗

Summary

Open-label Phase 1 pharmacokinetics study of omacetaxine mepesuccinate; the trial completed, investigating PK in hematologic malignancies and solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies
• Solid Tumors

Drugs mentioned

• Synribo (omacetaxine mepesuccinate)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Hematologic Malignancies, Solid Tumors | Phase 1 | Status: COMPLETED